U.S. Markets open in 3 hrs 46 mins

Analyst Sees 35% Upside in Shares of Biomerica, Inc.

NEW YORK, NY / ACCESSWIRE / September 20, 2017 / Zacks Small-Cap Research (''Zacks''), a leading provider of investment information and stock research reports, has recently published an in-depth report on Biomerica, Inc. (BMRA) (the ''Company''), a global biomedical company that develops, manufactures and markets advanced diagnostic products for the early detection of medical conditions and diseases.

The report from Zacks, which is available for free download here, shows that shares of the Company have over 35% upside based on a hybrid Price-to-Sales and Price-to-Book valuation of $3.75 per share. Mr. Brian Marckx, CFA, who authored the report, is a Director of Research at Zacks Investment Research, Inc. and also the Senior Medical Technology, Medical Device, and Diagnostics Analyst since 2007.

As of late, the Company has had some noteworthy developments. On August 16th, 2017, the Company announced an agreement with a multinational pharmaceutical company for product distribution in Mexico. On August 29th, 2017, the Company filed its 10-K Annual Report with the SEC, followed by an announcement of financial results on August 30th, 2017 which showed a fiscal year net sales increase of 12.7% over the prior year as well as a roughly 39% increase in revenues attributable to Asia.

Financial achievements aside, the Company just announced the initiation of clinical studies to evaluate the performance of its new and proprietary Helicobacter pylori (H. pylori) test. Zackary Irani, Chief Executive Officer of Biomerica, commented, ''The bacterium is a common cause of stomach ulcers and for certain individuals, stomach cancer. In Northern Europe and the United States, approximately one-third of adults are infected with H. pylori, while in Southern and Eastern Europe, South America and Asia, the prevalence is often greater than 50%.''

James Buxbaum, M.D., associate professor of clinical medicine at Keck School of Medicine of USC said, ''More accurate and reasonably priced diagnostic tests are needed to identify and direct H. Pylori therapy before it causes injury and cancer.''

''This is a large addressable market for Biomerica, and we are excited about the prospects for bringing a test which may improve the diagnosis and treatment of this disease, thereby improving patient outcomes, while providing the opportunity to generate substantial revenue growth for our company,'' concluded Mr. Irani.

For more in-depth analysis regarding Biomerica's recent financial results, operational updates, and upcoming developments, be sure to download the full 22-page report here.

About Biomerica, Inc. (BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.

The Biomerica InFoods® IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent-pending, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, prospects, new products, favorable outlook, new distributors, expansion, increases in productivity and margins, expected orders, leading market positions, anticipated future sales or production volume of the Company, the launch or success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

Contact Information

For questions or comments regarding the research report:

Brian Marckx, CFA
Zacks Small Cap Research
312-265-9474
bmarckx@zacks.com

For media inquiries or requests:

Grady Camp
Xposure Capital Markets, Inc.
917-361-5991
james@xposurecommunications.com

SOURCE: Xposure Capital Markets, Inc.